Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Health Care Poor Underserved ; 29(2): 573-580, 2018.
Article in English | MEDLINE | ID: mdl-29805123

ABSTRACT

Vulnerable populations are more likely to access medical care than visit a dentist. We introduced a dental team into a student-faculty collaborative clinic that serves a low-income Latino population. Documentation of oral exam findings rose from 11.88% to 50.50% in the year following integration of dental students into the clinic.


Subject(s)
Ambulatory Care Facilities/organization & administration , Cooperative Behavior , Dental Care/organization & administration , Faculty, Dental/psychology , Patient Care Team/organization & administration , Students, Dental/psychology , Adult , Dental Care/statistics & numerical data , Female , Humans , Male , Middle Aged , Program Evaluation , United States , Vulnerable Populations
2.
J Womens Health (Larchmt) ; 22(4): 322-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23540328

ABSTRACT

BACKGROUND: Metabolic Syndrome (MetSyn) is one of the strongest predictors of type 2 diabetes (DM2) and cardiovascular disease (CVD). It is associated with a 4- to 10-fold increased risk of DM2 and a 2- to 3-fold increased risk of CVD. Low income and minority women have some of the highest rates of MetSyn. This study examines the effect of a unique, community based, primary prevention program on the rates of MetSyn and health habits. METHODS: Sixty-four low income and minority women were enrolled in the HAPPY (Health Awareness and Primary Prevention in Your neighborhood) Heart Program in an eastern suburb of Boston. Over these 2 years, patients were evaluated by an interdisciplinary medical team: their primary physician, cardiologist, nutritionist, physical therapist, and health coach. The rate of MetSyn was measured at baseline, year 1, and year 2. Comparisons were made either using the paired t test for normally distributed variables or the Wilcoxon Sign test for non-normal variables. RESULTS: The rate of MetSyn fell from 64.7% at baseline to 34.9% at year 1 (p=0.01) and 28.2% at year 2 (p<0.001). This was driven by increases in high-density lipoprotein (HDL-C) (p<0.001) and decreases in blood pressure (p=0.05). Fasting blood glucose trended down, but the hemoglobin A1c (HbA1c) reached significance (decreasing from 6 to 5.8, p<0.01). Nutrition and exercise habits trended toward improvement. There were significant decreases in anxiety (p<0.001), depression (p=0.006) and stress (p=0.002). CONCLUSION: This lifestyle intervention program is effective at decreasing MetSyn in a socioeconomically disadvantaged, largely minority, female population. This program also decreases anxiety, stress, and depression among participants.


Subject(s)
Community Health Services , Metabolic Syndrome/prevention & control , Primary Prevention , Adult , Female , Humans , Life Style , Middle Aged , Poverty , Vulnerable Populations
3.
Cancer Res ; 66(17): 8542-9, 2006 Sep 01.
Article in English | MEDLINE | ID: mdl-16951166

ABSTRACT

Human beta-defensin-1 (hBD-1) is a candidate tumor suppressor gene located on chromosome 8p23. Previously, we showed that cancer-specific loss of hBD-1 was found in 90% of renal clear cell carcinomas and in 82% of prostate cancers. To investigate the possible mechanisms of decreased gene expression and determine the function of hBD-1 protein in urological cancers, we sequenced hBD-1 gene coding regions in prostatic and renal cancer samples. We then analyzed the frequency distribution of promoter polymorphisms and determined the effect of these base changes on transcriptional activity of the hBD-1 promoter. A polymorphism at -688 bases upstream of the ATG start codon affects hBD-1 promoter activity, leading to a rate of reporter gene transcription that is 40% to 50% lower than the wild-type sequence when tested in either DU145 or TSU-Pr1 cell lines. In addition, a polymorphism at -44 bases was shown to enhance transcription up to 2.3 times more than the wild-type sequence in the same cell lines. In addition, three novel hBD-1 promoter mutations were found in renal and prostate cancer clinical samples. An iso-5-aza-2'-deoxycytidine treatment was effective in transcription up-regulation in DU145, suggesting a possible upstream methylation-dependent effect. Synthetic hBD-1 peptide inhibited bladder cancer cell TSU-Pr1 proliferation. Overexpression of the hBD-1 gene in renal cancer cells SW156 resulted in caspase-3-mediated apoptosis. These data support the hypothesis that hBD-1 is a potential tumor suppressor gene for urological cancers. Promoter point mutations may be responsible for cancer-specific loss of hDB-1 expression.


Subject(s)
Apoptosis/physiology , Carcinoma, Renal Cell/genetics , Chromosomes, Human, Pair 8 , Genes, Tumor Suppressor , Kidney Neoplasms/genetics , Transcription, Genetic , beta-Defensins/genetics , Base Sequence , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , DNA Mutational Analysis , DNA, Neoplasm/genetics , Genome , Humans , Kidney Neoplasms/pathology , Male , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology
4.
J Urol ; 175(2): 468-72; discussion 472-3, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16406974

ABSTRACT

PURPOSE: While the mitochondrion is known to be a key mediator of apoptosis, there has been little inquiry into the inheritance pattern of mitochondria in patients with cancer. We compared the mtDNA haplotype in patients with prostate and renal cancer to that in controls to determine if there is an association between mitochondrial genotype and cancer. MATERIALS AND METHODS: Haplotyping was performed using polymerase chain reaction/digest identification of key polymorphic sites in the mitochondrial genome. A total of 121 and 221 white men with renal and prostate cancer, respectively, were identified following pathological confirmation of cancer, while 246 white controls were selected randomly from a bank of cadaveric organ donor DNA. Statistical analysis was performed and ORs were calculated. RESULTS: Mitochondrial haplogroup U was a highly significant risk factor for prostate and renal cancer vs controls (16.74% and 20.66% vs 9.35%, Fisher's exact test p = 0.019 and 0.005, respectively). The association remained statistically significant in renal cancer even after Bonferroni adjustment for multiple comparisons. Haplogroup U carried an OR of 1.95 for prostate cancer and an OR of 2.52 for renal cancer. CONCLUSIONS: The inheritance of mitochondrial haplogroup U is associated with an approximately 2-fold increased risk of prostate cancer and 2.5-fold increased risk of renal cancer in white North American individuals. Therefore, individuals with this mitochondrial haplotype are in a high risk group. Because mitochondrial haplogroup U is found in 9.35% of the white United States population, there are more than 20 million individuals in this high risk group.


Subject(s)
DNA, Mitochondrial/genetics , Haplotypes , Kidney Neoplasms/genetics , Prostatic Neoplasms/genetics , White People , Adolescent , Adult , Aged , Aged, 80 and over , Humans , Male , Middle Aged , North America
SELECTION OF CITATIONS
SEARCH DETAIL
...